AbbVie (ABBV) said to win its case against Coherus (CHRS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Abbvie (ABBV) PTAB Decision Incrementally Positive, But Does Not Change Cautious Thesis - BMO
November 7, 2016 1:40 PM ESTBMO Capital analyst Alex Arfaei weighed in on Abbvie (NYSE: ABBV), calling the PTAB denying institution of the Coherus (NASDAQ; CHRS) IPR of Humira formulation patent is incrementally positive for ABBV, but it does not change their cautious thesis
Arfaei commented, "We still see... More
Coherus BioSciences (CHRS) Receives Adverse PTAB Decision Over HUMIRA IPR
November 7, 2016 12:40 PM ESTCoherus BioSciences, Inc. (Nasdaq: CHRS) announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office denying institution of Coherus petition for Inter Partes Review (IPR) of AbbVies U.S. Patent 9,114,166 (the 166... More
AbbVie (ABBV) Surges Higher
November 7, 2016 12:11 PM ESTAbbVie (NYSE: ABBV) surges higher, which could be related to Coherus BioSciences (NASDAQ: CHRS) plunge.
... More
